Legal & General Group Plc reduced its position in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 41.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 139,075 shares of the company's stock after selling 99,741 shares during the quarter. Legal & General Group Plc owned about 0.20% of Bicycle Therapeutics worth $1,947,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Avior Wealth Management LLC purchased a new stake in Bicycle Therapeutics during the 4th quarter valued at $57,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Bicycle Therapeutics by 30.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock valued at $131,000 after acquiring an additional 2,191 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Bicycle Therapeutics by 26.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock worth $191,000 after acquiring an additional 1,782 shares during the last quarter. Jane Street Group LLC boosted its stake in shares of Bicycle Therapeutics by 35.7% during the 3rd quarter. Jane Street Group LLC now owns 20,180 shares of the company's stock worth $457,000 after purchasing an additional 5,310 shares during the period. Finally, EntryPoint Capital LLC bought a new position in Bicycle Therapeutics during the 4th quarter valued at about $614,000. 86.15% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
BCYC has been the subject of several analyst reports. Needham & Company LLC reissued a "buy" rating and issued a $30.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, April 9th. Stephens restated an "equal weight" rating and set a $15.00 price objective on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd. Finally, HC Wainwright reiterated a "buy" rating and issued a $33.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $29.14.
View Our Latest Report on Bicycle Therapeutics
Bicycle Therapeutics Stock Performance
NASDAQ BCYC traded up $0.35 on Wednesday, reaching $8.56. 414,329 shares of the stock traded hands, compared to its average volume of 397,616. Bicycle Therapeutics plc has a 12 month low of $6.10 and a 12 month high of $28.67. The company has a fifty day moving average price of $8.79 and a 200-day moving average price of $14.72. The company has a market cap of $592.37 million, a price-to-earnings ratio of -2.60 and a beta of 1.40.
Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.10. The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.47 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. Bicycle Therapeutics's revenue was down 30.2% compared to the same quarter last year. During the same period last year, the company posted ($1.16) earnings per share. As a group, research analysts anticipate that Bicycle Therapeutics plc will post -3.06 earnings per share for the current fiscal year.
Bicycle Therapeutics Company Profile
(
Free Report)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
Recommended Stories
Before you consider Bicycle Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.
While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
